Back to News
Market Impact: 0.3
What Alkermes (ALKS) Said on Its Q3 Earnings Call
Source: marketbeat.com
Corporate EarningsHealthcare & BiotechCompany Fundamentals
Alkermes reported 31% year-over-year growth in proprietary product sales in the third quarter of 2026. Management also highlighted continued investment in its orexin development portfolio spanning sleep, neuropsychiatric and neurological disorders.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.35
Ticker Sentiment
ALKS0.55
More News
- Binance co-CEO Richard Teng says hackers used fake job interviews, AI tool to steal $6.3 billion in crypto 108511116
- AMD stock jumps 7% on earnings as data center revenue nearly doubles
- Marvell Technology could plunge on latest multibillion-dollar acquisition
- Disney Plans Thousands of Layoffs Companywide
- AMD rides data center riches to ‘largest and most profitable’ quarter in history
- AMD’s OpenAI, Meta chip deals trigger $1 billion quarterly charge